These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8455048)

  • 21. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symmetry analysis for monitoring safety of newly marketed drugs.
    Kubota K
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):349-51. PubMed ID: 26440748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse drug reaction monitoring: doing it the French way.
    Moore N; Biour M; Paux G; Loupi E; Begaud B; Boismare F; Royer RJ
    Lancet; 1985 Nov; 2(8463):1056-8. PubMed ID: 2865527
    [No Abstract]   [Full Text] [Related]  

  • 24. A positive event dependence model for self-controlled case series with applications in postmarketing surveillance.
    Simpson SE
    Biometrics; 2013 Mar; 69(1):128-36. PubMed ID: 23006045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes.
    Vaccine; 2013 Dec; 31 Suppl 10():K1. PubMed ID: 24331068
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluating and monitoring the safety and efficacy of drug therapy and surgery.
    Stolley PD; Strom BL
    J Chronic Dis; 1986; 39(12):1145-55. PubMed ID: 3539972
    [No Abstract]   [Full Text] [Related]  

  • 27. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel C; Scosyrev E; Petrin M; Schmouder R
    Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Better reporting of adverse drug reactions.
    Abrutyn E
    Ann Intern Med; 1985 Feb; 102(2):264-5. PubMed ID: 3966766
    [No Abstract]   [Full Text] [Related]  

  • 29. What is pharmacoepidemiology? Definition, methods, interest and clinical applications.
    Montastruc JL; Benevent J; Montastruc F; Bagheri H; Despas F; Lapeyre-Mestre M; Sommet A
    Therapie; 2019 Apr; 74(2):169-174. PubMed ID: 30389102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A statistical methodology for postmarketing surveillance of adverse drug reaction reports.
    Norwood PK; Sampson AR
    Stat Med; 1988 Oct; 7(10):1023-30. PubMed ID: 3206000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives on the future of postmarket vaccine safety surveillance and evaluation.
    Ball R
    Expert Rev Vaccines; 2014 Apr; 13(4):455-62. PubMed ID: 24606417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance.
    Silva IR; Kulldorff M
    Biometrics; 2015 Sep; 71(3):851-8. PubMed ID: 26011024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing alerting thresholds for prospective drug safety monitoring.
    Wangge G; Schneeweiss S; Glynn RJ; Gagne JJ
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):755-62. PubMed ID: 26596260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse reactions to new drugs.
    Venning GR
    Br Med J (Clin Res Ed); 1983 Mar; 286(6370):1052-3. PubMed ID: 6403183
    [No Abstract]   [Full Text] [Related]  

  • 36. When should case-only designs be used for safety monitoring of medical products?
    Maclure M; Fireman B; Nelson JC; Hua W; Shoaibi A; Paredes A; Madigan D
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():50-61. PubMed ID: 22262593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The rationale for a post-marketing surveillance.
    Westerholm B
    Hum Reprod; 1987 Jan; 2(1):41-4. PubMed ID: 3571446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Erice Manifesto: for global reform of the safety of medicines in patient care.
    Drug Saf; 2007; 30(3):187-90. PubMed ID: 17343426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study.
    Poirot E; Soble A; Ntshalintshali N; Mwandemele A; Mkhonta N; Malambe C; Vilakati S; Pan S; Darteh S; Maphalala G; Brown J; Hwang J; Pace C; Stergachis A; Vittinghoff E; Kunene S; Gosling R
    Malar J; 2016 Jul; 15(1):384. PubMed ID: 27450652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
    Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
    Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.